Lanean...
Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by...
Gorde:
| Argitaratua izan da: | F1000Res |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
F1000 Research Limited
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222031/ https://ncbi.nlm.nih.gov/pubmed/32489646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.22877.1 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|